Abstract
A major transformation in dementia diagnosis and care appears imminent and will depend on three major types of biomarkers: molecular imaging, blood-based biomarkers, and cerebrospinal fluid biomarkers. Each modality has unique strengths and limitations that suggest its optimal uses in research, clinical trials, and clinical diagnosis.